Kaiser program dramatically cuts vertical hep B transmission
Kaiser program dramatically cuts vertical hep B transmission
By Megan Brooks
NEW YORK (Reuters Health) - A comprehensive program of
prenatal hepatitis B virus (HBV) screening followed by postnatal
immunoprophylaxis with hepatitis B immunoglobulin is proving
highly effective at preventing perinatal HBV transmission at
Kaiser Permanente Northern California, researchers there say.
Their observational study also shows that the highest risk
of transmission is in e antigen-positive mothers with very high
viral load (>50 million IU/mL).
"This group of women may benefit from additional therapy to
prevent vertical transmission. However, for others, the risk of
transmission is extremely low as long as the infants are
immunized according to the guideline," Dr. Ai Kubo of Kaiser
Permanente Division of Research in Oakland, California, who
co-led the study with Dr. Lyle Shlager of Kaiser Permanente San
Francisco Medical Center, told Reuters Health by email.
The Centers for Disease Control and Prevention (CDC)
recommends that pregnant women be screened for HBV and that
infants of HBV-positive mothers receive immunoprophylaxis.
"Our findings do support current guidelines in a way that
with adherence, the rate of transmission was very low, which is
the purpose of the guideline," Dr. Kubo said. "The CDC
guideline works for the majority of infants in preventing
vertical transmission, if the immunizations are done according
to the recommended schedule."
As reported online May 26 in Annals of Internal Medicine,
the researchers examined the health records for 4,446 infants
born to 3,253 HBV-positive mothers between 1997 and 2010 within
Kaiser Permanente Northern California, an integrated health
services delivery organization with roughly 3.3 million members.
The infant infection rate was 0.75 per 100 births from 1997
to 2010. Rates per 100 births were 3.37 for e antigen-positive
mothers compared with 0.04 for e antigen-negative mothers.
Among mothers with known viral loads, the lowest level
associated with transmission was 6.32 x 10^7 IU/mL. Infection
rates per 100 births were 3.61 among the 83 births to mothers
with viral loads of 5 x 10^7 IU/mL or greater and 0 among the
831 births to mothers with viral loads lower than this level,
regardless of e antigen status.
"Until now, nobody has really known who to treat," Dr.
Shlager noted in an interview with Reuters Health. "This study
identifies the women that are at highest risk for transmitting
hepatitis B to their child, who may need a secondary therapy
like an oral antiviral medication to lower the viral load of the
mother before they deliver to prevent transmission in these very
high risk births," he said.
Kaiser Permanente Northern California's Perinatal Hepatitis
B Screening Program "case-manages each mother-infant pair (if
positive for HepB), enabling the almost complete immunization
rate. This is important, as without an organized effort,
immunization and follow-up rates can be low, and there is
greater chance of transmission," Dr. Kubo said.
"The program has been in effect since 1988 and it has
evolved over the years," Dena Lakritz, the program's nurse
coordinator, told Reuters Health by phone. "We make sure that
every (pregnant) patient has a hepatitis B test . . . We look at
all aspects of patient care and don't leave any stone unturned.
We interact with all the ob/gyn offices in northern California,
the pediatrician offices, and the regional labs."
"The program is very successful and incredibly well-run
centrally," Dr. Shlager added.
The study was funded by Kaiser Permanente Community Benefit
and the National Institutes of Health.
SOURCE: http://bit.ly/1h9QZAh
Ann Intern Med 2014.
|